[go: up one dir, main page]

WO2004075875A8 - Dosage form having a saccharide matrix - Google Patents

Dosage form having a saccharide matrix

Info

Publication number
WO2004075875A8
WO2004075875A8 PCT/DK2004/000119 DK2004000119W WO2004075875A8 WO 2004075875 A8 WO2004075875 A8 WO 2004075875A8 DK 2004000119 W DK2004000119 W DK 2004000119W WO 2004075875 A8 WO2004075875 A8 WO 2004075875A8
Authority
WO
WIPO (PCT)
Prior art keywords
dosage form
saccharide matrix
active substance
forming agent
matrix forming
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DK2004/000119
Other languages
French (fr)
Other versions
WO2004075875A1 (en
Inventor
Christian Gauguin Houghton
Annette Roemmelmaye Lundegaard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ALK Abello AS
Original Assignee
ALK Abello AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ALK Abello AS filed Critical ALK Abello AS
Priority to MXPA05009079A priority Critical patent/MXPA05009079A/en
Priority to CA2516291A priority patent/CA2516291C/en
Priority to KR1020057015834A priority patent/KR101136573B1/en
Priority to JP2006501528A priority patent/JP4688787B2/en
Priority to CN2004800053662A priority patent/CN1758899B/en
Priority to EP04713847A priority patent/EP1599185A1/en
Priority to HK06109448.3A priority patent/HK1089083B/en
Priority to AU2004216559A priority patent/AU2004216559B2/en
Publication of WO2004075875A1 publication Critical patent/WO2004075875A1/en
Publication of WO2004075875A8 publication Critical patent/WO2004075875A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a non-compressed fast-dispersing solid dosage form suitable for oromucosal administration of a pharmaceutically active substance comprising (a) a first matrix forming agent in the form of maltodextrin having a dextrose equivalent (DE) of between 1 and 20,(b) a second matrix forming agent in the form of sorbitol, and (c) the active substance.
PCT/DK2004/000119 2003-02-28 2004-02-24 Dosage form having a saccharide matrix Ceased WO2004075875A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
MXPA05009079A MXPA05009079A (en) 2003-02-28 2004-02-24 Dosage form having a saccharide matrix.
CA2516291A CA2516291C (en) 2003-02-28 2004-02-24 Dosage form having a saccharide matrix
KR1020057015834A KR101136573B1 (en) 2003-02-28 2004-02-24 Dosage form having a saccharide matrix
JP2006501528A JP4688787B2 (en) 2003-02-28 2004-02-24 Dosage form with saccharide matrix
CN2004800053662A CN1758899B (en) 2003-02-28 2004-02-24 Dosage forms with sugar base
EP04713847A EP1599185A1 (en) 2003-02-28 2004-02-24 Dosage form having a saccharide matrix
HK06109448.3A HK1089083B (en) 2003-02-28 2004-02-24 Dosage form having a saccharide matrix
AU2004216559A AU2004216559B2 (en) 2003-02-28 2004-02-24 Dosage form having a saccharide matrix

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200300318 2003-02-28
DKPA200300318 2003-02-28
US46538303P 2003-04-25 2003-04-25
US60/465,383 2003-04-25

Publications (2)

Publication Number Publication Date
WO2004075875A1 WO2004075875A1 (en) 2004-09-10
WO2004075875A8 true WO2004075875A8 (en) 2004-12-29

Family

ID=32929063

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2004/000119 Ceased WO2004075875A1 (en) 2003-02-28 2004-02-24 Dosage form having a saccharide matrix

Country Status (8)

Country Link
EP (1) EP1599185A1 (en)
JP (1) JP4688787B2 (en)
KR (1) KR101136573B1 (en)
AU (1) AU2004216559B2 (en)
CA (1) CA2516291C (en)
MX (1) MXPA05009079A (en)
PL (1) PL210707B1 (en)
WO (1) WO2004075875A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060210590A1 (en) 2005-02-03 2006-09-21 Alk-Abello A/S Minor allergen control to increase safety of immunotherapy
RU2008117396A (en) 2005-10-04 2009-11-10 Альк-Абелло А/С (Dk) SOLID VACCINE COMPOSITION
US12186426B2 (en) 2009-10-30 2025-01-07 Ix Biopharma Ltd. Solid dosage form
EP3254676B1 (en) 2009-10-30 2018-11-28 IX Biopharma Ltd Fast dissolving solid dosage form
PL2552418T3 (en) 2010-03-29 2017-12-29 Ferring B.V. A fast dissolving pharmaceutical composition
JO3112B1 (en) 2010-03-29 2017-09-20 Ferring Bv A fast dissolving pharmaceutical composition
JP5800527B2 (en) * 2010-03-30 2015-10-28 日東電工株式会社 Stabilized pharmaceutical composition, stabilized pharmaceutical composition solution preparation, film-form preparation and method for producing film-form preparation
EP2635264B8 (en) * 2010-11-04 2018-07-18 Norgine B.V. Formulations comprising polyethylene glycol
JP2012240975A (en) * 2011-05-20 2012-12-10 Nitto Denko Corp Pharmaceutical composition and jerry-form preparation
JP2012240978A (en) * 2011-05-20 2012-12-10 Nitto Denko Corp Pharmaceutical composition and gelatinous preparation
US9731018B2 (en) 2011-09-16 2017-08-15 Ferring B.V. Fast dissolving pharmaceutical composition
CN109125283A (en) * 2013-03-14 2019-01-04 艾慕恩治疗公司 The preparation of peanut preparation for oral desensitization
US9492535B2 (en) 2013-03-14 2016-11-15 Aimmune Therapeutics, Inc. Peanut formulations and uses thereof
EP2952200A1 (en) 2014-06-04 2015-12-09 Alk-Abelló A/S Allergen for prophylactic treatment of allergy
GB2545880A (en) 2015-10-20 2017-07-05 Glide Pharmaceutical Tech Ltd Solid formulation
KR20200093608A (en) * 2017-11-27 2020-08-05 디에스엠 아이피 어셋츠 비.브이. Freeze-dried multiparticulate solid dosage form
WO2019146777A1 (en) * 2018-01-29 2019-08-01 株式会社リタファーマ Pharmaceutical formulation and production method for same
WO2020037151A1 (en) 2018-08-16 2020-02-20 Aimmune Therapeutics, Inc. Peanut oral immunotherapy with maintenance dose
CN120789028A (en) 2018-09-07 2025-10-17 阿奎蒂夫疗法公司 Oral film compositions and dosage forms having precise active dissolution profiles
CA3123605A1 (en) 2018-12-20 2020-06-25 Aimmune Therapeutics, Inc. Peanut oral immunotherapy dosing schedule for missed doses
WO2020231843A1 (en) 2019-05-10 2020-11-19 Aimmune Therapeutics, Inc. Methods for improving the quality of life of a patient with a peanut allergy
CN116891827B (en) * 2023-09-08 2024-01-30 山东康华生物医疗科技股份有限公司 NK cell activity activation system

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD107208A1 (en) 1973-06-04 1974-07-20
IE45770B1 (en) * 1976-10-06 1982-11-17 Wyeth John & Brother Ltd Pharmaceutical dosage forms
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
FR2609895B1 (en) 1987-01-28 1991-06-28 Bruttmann Georges NEW GALENIC FORMS OF ALLERGENS FOR PER- AND SUB-LINGUAL ADMINISTRATION
US5215756A (en) 1989-12-22 1993-06-01 Gole Dilip J Preparation of pharmaceutical and other matrix systems by solid-state dissolution
US5558880A (en) 1989-12-22 1996-09-24 Janssen Pharmaceutica Inc. Pharmaceutical and other dosage forms
US6337082B1 (en) 1991-10-25 2002-01-08 Biovail Tech Ltd Saccharide-based matrix
US5343762A (en) 1992-10-05 1994-09-06 Rosemount Inc. Vortex flowmeter
US5343672A (en) 1992-12-01 1994-09-06 Scherer Ltd R P Method for manufacturing freeze dried dosages in a multilaminate blister pack
CN1120310A (en) * 1993-03-11 1996-04-10 塞科雷泰克公司 Polymeric mucoadhesives in the delivery of immunogens at mucosal surfaces
US6010719A (en) * 1997-09-16 2000-01-04 Universiteit Gent Freeze-dried disintegrating tablets
US20020197321A1 (en) * 1997-10-27 2002-12-26 Harry Seager Solid dispersing vaccine composition for oral delivery
GB9722682D0 (en) * 1997-10-27 1997-12-24 Scherer Ltd R P Pharmaceutical products
NZ506665A (en) 1998-03-16 2003-08-29 Alk Abello As Mutant recombinant allergens
GB9901819D0 (en) * 1999-01-27 1999-03-17 Scherer Corp R P Pharmaceutical compositions
FR2790387B1 (en) 1999-03-01 2001-05-18 Prographarm Laboratoires ORODISPERSIBLE TABLET HAVING LOW FRIABILITY AND PROCESS FOR THE PREPARATION THEREOF
US20060073188A1 (en) * 1999-03-31 2006-04-06 Pierre Fabre Medicament Fast-dissolving isotropic expanded microporous composition or structure for pharmaceutical, veterinary, dietetic, food or cosmetic use and method for obtaining same
FR2791569B1 (en) * 1999-03-31 2003-05-09 Pf Medicament ISOTROPIC FAST DISSOLVING ISOTROPIC MICROPOROUS COMPOSITION OR STRUCTURE FOR PHARMACEUTICAL, VETERINARY, DIETETIC, FOOD OR COSMETIC USE AND PROCESS FOR OBTAINING THE SAME
GB9908014D0 (en) 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
HUP0202537A3 (en) * 1999-08-24 2004-05-28 Teva Pharma A vaccine composition and method of using the same
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
DE19951970A1 (en) * 1999-10-28 2001-05-03 Bionetworks Gmbh Medicines for tolerance induction
GB0020089D0 (en) 2000-08-15 2000-10-04 Smithkline Beecham Biolog Vaccine Composition
DK1373510T3 (en) 2000-11-16 2009-02-23 Alk Abello As Mutant allergens
US6733781B2 (en) * 2000-12-06 2004-05-11 Wyeth Fast dissolving tablet
ITMI20010571A1 (en) * 2001-03-19 2002-09-19 Grisotech S A TRANS-MUCOSAL ABSORBABLE VACCINES
WO2003096869A2 (en) 2002-05-16 2003-11-27 Alk Abelló A/S Recombinant bet. v. 1. allergen mutants, methods and process thereof

Also Published As

Publication number Publication date
WO2004075875A1 (en) 2004-09-10
PL378543A1 (en) 2006-05-02
CA2516291C (en) 2012-02-14
HK1089083A1 (en) 2006-11-24
AU2004216559B2 (en) 2010-05-27
PL210707B1 (en) 2012-02-29
KR101136573B1 (en) 2012-04-23
AU2004216559A1 (en) 2004-09-10
EP1599185A1 (en) 2005-11-30
KR20050105491A (en) 2005-11-04
MXPA05009079A (en) 2006-05-19
JP2006519187A (en) 2006-08-24
JP4688787B2 (en) 2011-05-25
CA2516291A1 (en) 2004-09-10

Similar Documents

Publication Publication Date Title
WO2004075875A8 (en) Dosage form having a saccharide matrix
WO2004047794A3 (en) An allergen dosage form
WO2004069198A3 (en) Sugar-free oral transmucosal solid dosage forms and uses thereof
WO2000041681A3 (en) MEDICINAL FORMULATIONS CONTAINING AN OPIOID AND AN α-ANTAGONIST
DK1183014T3 (en) Flavored controlled release oral pharmaceutical compositions
WO2008011169A3 (en) Controlled release formulations and associated methods
MXPA03007712A (en) Pharmaceutical salts.
WO2001089479A3 (en) Sustained release pharmaceutical compositions for parenteral administration of hydrophilic compounds
EE200200522A (en) The enzyme-cleaving peptide conjugated to the active ingredient, a pharmaceutical composition containing it and its use as an antitumor drug
WO2002024184A3 (en) Mechanically stable dosage forms containing ubiquinones
IL150528A0 (en) Ibuprofen containing active agent preparation
WO2007009806A3 (en) Solid dosage formulations of narcotic drugs having improved buccal adsorption
WO2005007137A3 (en) Tablets containing ambroxol
WO2005097076A3 (en) Low dose pharmaceutical products
BR0112847A (en) Use of a solid dosage form
WO2005004860A3 (en) Novel solid pharmaceutical composition comprising amisulpride
WO2002053149A3 (en) Medicament containing a polyamine as an active substance
WO2002034240A3 (en) Delayed and sustained release formulations and method of use thereof
DE60316714D1 (en) PHARMACEUTICAL FORMULATION CONTAINING OLANZAPINE
WO2003011247A3 (en) Support matrix comprising particles loaded with active ingredient for application on the skin or mucous membrane
EP1273301A3 (en) Pharmaceutical preparations based on active ingredients susceptible to illict administration
MY141008A (en) Oral formulations of deoxypeganine and their uses
UA93479C2 (en) Allergen dosage form
WO2007016350A3 (en) Modified release tablet formulations with enhanced mechanical properties
DE59510583D1 (en) PHARMACEUTICAL COMPOSITION FOR SYSTEMIC TRANSDERMAL ADMINISTRATION WITH THE ACTIVE MORPHINE-6-GLUCURONIDE

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 37/2004 UNDER (72)(75) THE ADDRESS OF "HOUGHTON, CHRISTIAN, GAUGUIN" SHOULD READ "C.L. IBSENSVEJ 23 B"

WWE Wipo information: entry into national phase

Ref document number: 2516291

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004216559

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/009079

Country of ref document: MX

Ref document number: 1020057015834

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2006501528

Country of ref document: JP

Ref document number: 20048053662

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 378543

Country of ref document: PL

ENP Entry into the national phase

Ref document number: 2004216559

Country of ref document: AU

Date of ref document: 20040224

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004216559

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004713847

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020057015834

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004713847

Country of ref document: EP

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)